AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8098238 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 3516
Study 8098238 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms four times a day)
Number of subjects: 3516
Study 8098238 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 3516
Study 8098238 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 3516
Study 8098238 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol and Salbutamol
Number of subjects: 3516
Study 3327022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine combination therapy (COP)
Number of subjects: 0
Study 3327022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine combination therapy (CEP)
Number of subjects: 0
Study 3327022 — intervention group
Group type: COMPARATOR
Intervention: Vincristine
Number of subjects: 0
Study 3327022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine
Number of subjects: 0
Study 31990954 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill workstation intervention
Number of subjects: 20
Study 28730676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (ING) 1 mg
Number of subjects: 10
Study 28730676 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (INP)
Number of subjects: 10
Study 26512029 — intervention group
Group type: EXPERIMENTAL
Intervention: High knowledge scores
Number of subjects: 423
Study 26512029 — intervention group
Group type: EXPERIMENTAL
Intervention: High practice scores
Number of subjects: 423
Study 26512029 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate knowledge and practice scores
Number of subjects: 423
Study 24731783 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment after 6 months
Number of subjects: 60
Study 24731783 — intervention group
Group type: COMPARATOR
Intervention: Control group (no natalizumab treatment)
Number of subjects: 60
Study 23525453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bevacizumab (300 mg) with cisplatin (30 mg)
Number of subjects: 72
Study 23525453 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural cisplatin (30 mg) alone
Number of subjects: 72
Study 19826855 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills and neurocognitive individualized training (SSANIT)
Number of subjects: 60
Study 19826855 — intervention group
Group type: COMPARATOR
Intervention: Structured leisure activities (SLA)
Number of subjects: 60
Study 18568412 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (610 mg orally every other day for 2 months)
Number of subjects: 47
Study 18568412 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate therapy (control group)
Number of subjects: 47
Study 16622610 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PCI within 2 hours
Number of subjects: 451
Study 16622610 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCI after 12-72 hours
Number of subjects: 451
Study 12901032 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 16
Study 12901032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 16
Study 12901032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both COX‐2 inhibitors
Number of subjects: 16
Study 12901032 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 16
Study 11218488 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inlays (Tetric, blend‐a‐lux, Pertac)
Number of subjects: 71
Study 11218488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlays (Empress)
Number of subjects: 71
Study 11218488 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlays in small cavities
Number of subjects: 71
Study 11218488 — intervention group
Group type: COMPARATOR
Intervention: Molar inlays
Number of subjects: 71
Study 8972810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota‐dent (Rota‐dent, Kusnacht, Switzerland)
Number of subjects: 38
Study 8972810 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plaque Remover (Braun/Oral‐B, Kronberg, Germany)
Number of subjects: 38
Study 8972810 — intervention group
Group type: EXPERIMENTAL
Intervention: Interplak (Bausch & Lomb, Berlin, Germany)
Number of subjects: 38
Study 8972810 — intervention group
Group type: COMPARATOR
Intervention: Manual technique (normal toothbrush, interdental brush, dental floss)
Number of subjects: 38
Study 8972810 — intervention group
Group type: EXPERIMENTAL
Intervention: All electric toothbrushes
Number of subjects: 38
Study 1281177 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge in allergic patients
Number of subjects: 24
Study 6084675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g 1 h pre‐operatively and every 6 h for 48 h (vein graft patients)
Number of subjects: 140
Study 6084675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vein graft patients)
Number of subjects: 140
Study 6084675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g (synthetic graft patients)
Number of subjects: 140
Study 6084675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g (synthetic graft patients)
Number of subjects: 140
Study 29266047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory feedback (acoustic/vibration) for face-down positioning after macular hole surgery
Number of subjects: 48
Study 29266047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory feedback (acoustic/vibration) for side positioning after retinal detachment surgery
Number of subjects: 48
Study 29266047 — intervention group
Group type: COMPARATOR
Intervention: Instructional methods (verbal/illustrated)
Number of subjects: 48
Study 29266047 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires regarding sensor acceptance
Number of subjects: 48
Study 29159993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 110
Study 29159993 — intervention group
Group type: COMPARATOR
Intervention: General dietary advice (GDA)
Number of subjects: 110
Study 27687379 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Qsp (Group A: n = 20)
Number of subjects: 37
Study 27687379 — intervention group
Group type: COMPARATOR
Intervention: i-Gel (Group I: n = 17)
Number of subjects: 37
Study 27687379 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Qsp (Group A)
Number of subjects: 37
Study 27687379 — intervention group
Group type: COMPARATOR
Intervention: i-Gel (Group I)
Number of subjects: 37
Study 24315706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) - five walking sessions per week at 55‐100% of peak oxygen uptake (VO2peak) for 30‐60 min per session
Number of subjects: 50
Study 24315706 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 50
Study 24315706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 50
Study 23424961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (Flu) 20 mg/day
Number of subjects: 18
Study 20473992 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA (VNUS ClosureFAST)
Number of subjects: 131
Study 20473992 — intervention group
Group type: COMPARATOR
Intervention: EVLA (980 nm)
Number of subjects: 131
Study 18384551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (7 mg)
Number of subjects: 24
Study 18384551 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 24
Study 18384551 — intervention group
Group type: COMPARATOR
Intervention: No patch
Number of subjects: 24
Study 16181170 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention by an expert physical/occupational therapist
Number of subjects: 84
Study 16181170 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study 14623733 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 10
Study 14623733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10674566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide (400 microg) once daily for 4 weeks
Number of subjects: 242
Study 10674566 — intervention group
Group type: COMPARATOR
Intervention: Aqueous spray (256 microg) once daily for 4 weeks
Number of subjects: 242
Study 8961989 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery preceded by 40 Gy radiotherapy (20 fractions of 2 Gy over 4 weeks)
Number of subjects: 279
Study 8961989 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 279
Study 8961989 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery preceded by 40 Gy radiotherapy
Number of subjects: 279
Study 1553856 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.125 mg intravenous (IV) prochlorperazine
Number of subjects: 6
Study 1553856 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral prochlorperazine
Number of subjects: 6
Study 3857405 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (Cp) injections, both intradermal (i.c.) and subcutaneous (s.c.)
Number of subjects: 0
Study 3857405 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (Cp) injections
Number of subjects: 0
Study 28984157 — intervention group
Group type: EXPERIMENTAL
Intervention: BADI intervention
Number of subjects: 1077
Study 28984157 — intervention group
Group type: EXPERIMENTAL
Intervention: BADI intervention with therapist support
Number of subjects: 1077
Study 27035371 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing Lactobacillus reuteri DSM 17938 (CLr)
Number of subjects: 40
Study 27035371 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CCt)
Number of subjects: 40
Study 27035371 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing Lactobacillus reuteri DSM 17938 (VLr)
Number of subjects: 40
Study 27035371 — intervention group
Group type: COMPARATOR
Intervention: Control formula (VCt)
Number of subjects: 40
Study 23909409 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin (30 mg oral dose)
Number of subjects: 8
Study 23909409 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (30 mg oral dose of alitretinoin)
Number of subjects: 8
Study 22449647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hitkashrut co-parent training program
Number of subjects: 209
Study 22449647 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 209
Study 19889036 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Symptom Severity Index (SSI)
Number of subjects: 108
Study 18672768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 18672768 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 90
Study 18672768 — intervention group
Group type: COMPARATOR
Intervention: Somiton tablet (Control)
Number of subjects: 90
Study 16204431 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg at 9:00 AM, 1:00 PM, and 6:00 PM after 5 days of abstinence from caffeine
Number of subjects: 96
Study 16204431 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 300 mg/day and 600 mg/day for 5 days prior to challenge
Number of subjects: 96
Study 16204431 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg (control)
Number of subjects: 96
Study 15984440 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX)
Number of subjects: 0
Study 12403222 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy at 20 ppm weaned to 5 ppm over 24-48 hours
Number of subjects: 34
Study 12403222 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO therapy)
Number of subjects: 34
Study 10464845 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐134a BDP, 1600 mg total dose
Number of subjects: 0
Study 10464845 — intervention group
Group type: COMPARATOR
Intervention: CFC‐11/12 BDP, 2000 mg total dose
Number of subjects: 0
Study 10464845 — intervention group
Group type: COMPARATOR
Intervention: HFA‐134a placebo
Number of subjects: 0
Study 10464845 — intervention group
Group type: COMPARATOR
Intervention: CFC‐11/12 placebo
Number of subjects: 0
Study 10464845 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐134a BDP
Number of subjects: 0
Study 10464845 — intervention group
Group type: COMPARATOR
Intervention: CFC‐11/12 BDP
Number of subjects: 0
Study 7790534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (CHX) rinse for 1 min
Number of subjects: 24
Study 7790534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (CHX) irrigation for 15 s
Number of subjects: 24
Study 7790534 — intervention group
Group type: COMPARATOR
Intervention: saline rinse for 1 min
Number of subjects: 24
Study 7790534 — intervention group
Group type: COMPARATOR
Intervention: saline irrigation for 15 s
Number of subjects: 24
Study 2284328 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl daily per os
Number of subjects: 51
Study 2284328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6776569 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoctamide hydrogen succinate (600 mg)
Number of subjects: 6
Study 6776569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (linolenic acid)
Number of subjects: 6
Study 6419633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam i.m.
Number of subjects: 10
Study 6419633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg midazolam i.m.
Number of subjects: 10
Study 6419633 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg diazepam i.m.
Number of subjects: 10
Study 6419633 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/50 mg pethidine/promethazine i.m.
Number of subjects: 10
Study 6419633 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.m.
Number of subjects: 10
Study 30010085 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 516
Study 30010085 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials
Number of subjects: 516
Study 24855313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67
Study 24855313 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational (PED)
Number of subjects: 67
Study 24924849 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor-response execution resistance (ER)
Number of subjects: 0
Study 24924849 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor-repeat trial
Number of subjects: 0
Study 24924849 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice effect on error protection
Number of subjects: 0
Study 22040838 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with placebo (EP)
Number of subjects: 32
Study 22040838 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with metformin (EM)
Number of subjects: 32
Study 22040838 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 mg/day metformin (M)
Number of subjects: 32
Study 22040838 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 32
Study 20833613 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR counseling at community pharmacies
Number of subjects: 24
Study 18180434 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate OROS
Number of subjects: 21
Study 18180434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15823456 — intervention group
Group type: EXPERIMENTAL
Intervention: Meter A
Number of subjects: 409
Study 15823456 — intervention group
Group type: COMPARATOR
Intervention: Meter B
Number of subjects: 409
Study 15823456 — intervention group
Group type: EXPERIMENTAL
Intervention: Meter C
Number of subjects: 409
Study 12839321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 30
Study 12839321 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 30
Study 12839321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10664640 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.0 and 2.0 g/d of elemental calcium)
Number of subjects: 193
Study 10664640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 8793045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fat cow's milk
Number of subjects: 30
Study 8793045 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based nondairy drink
Number of subjects: 30
Study 1616164 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution, 10 mL epidurally and 3 mL intramuscularly (IM)
Number of subjects: 120
Study 1616164 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of epidural saline solution and 75 mg (3 mL) of diclofenac IM
Number of subjects: 120
Study 1616164 — intervention group
Group type: COMPARATOR
Intervention: 2 mg of morphine in 10 mL of epidural saline solution and 3 mL of saline solution IM
Number of subjects: 120
Study 1616164 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of morphine in 10 mL of epidural saline solution and 75 mg of diclofenac IM
Number of subjects: 120
Study 6717874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention management with oxytocin if labor did not ensue within 12 hours of rupture of membranes
Number of subjects: 134
Study 6717874 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (bed rest and observation)
Number of subjects: 134
Study 31141291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic navigation system for implant placement
Number of subjects: 14
Study 29314505 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring of BNP
Number of subjects: 107
Study 29314505 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving average filter (fBNP)
Number of subjects: 107
Study 27050177 — intervention group
Group type: EXPERIMENTAL
Intervention: 15ml natural honey applied on oral mucosa
Number of subjects: 28
Study 27050177 — intervention group
Group type: COMPARATOR
Intervention: 15ml plain water applied on oral mucosa (Control)
Number of subjects: 28
Study 25185289 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergopharma group
Number of subjects: 9233
Study 25185289 — intervention group
Group type: COMPARATOR
Intervention: Alutard‐SQ group
Number of subjects: 9233
Study 22793964 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (RE maintained between 45 and 59)
Number of subjects: 20
Study 22793964 — intervention group
Group type: COMPARATOR
Intervention: Group II (RE maintained between 30 and 44)
Number of subjects: 20
Study 19523697 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric ward management
Number of subjects: 45
Study 19523697 — intervention group
Group type: COMPARATOR
Intervention: Standard care management
Number of subjects: 45
Study 19023841 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention using urinary cotinine as an abstinence indicator
Number of subjects: 0
Study 19023841 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily immunoassay test strips for urinary cotinine
Number of subjects: 0
Study 19023841 — intervention group
Group type: COMPARATOR
Intervention: Daily multiple CO measurements
Number of subjects: 0
Study 15841628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch (30-minute application)
Number of subjects: 79
Study 15841628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30-minute application)
Number of subjects: 79
Study 12001006 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1% cream with sunscreen SPF 15
Number of subjects: 120
Study 12001006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle containing sunscreen with SPF 15)
Number of subjects: 120
Study 10367603 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed smokers
Number of subjects: 245
Study 10367603 — intervention group
Group type: COMPARATOR
Intervention: Control smokers
Number of subjects: 245
Study 10367603 — intervention group
Group type: COMPARATOR
Intervention: Control non-smokers
Number of subjects: 245
Study 10367603 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed non-smokers
Number of subjects: 245
Study 8652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 649
Study 8652857 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 649
Study 8652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Interferon-alpha and Hydroxyurea
Number of subjects: 649
Study 1793694 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative autotransfusion with pre-operative aspirin
Number of subjects: 21
Study 1793694 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative autotransfusion without pre-operative aspirin
Number of subjects: 21
Study 1793694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 21
Study 1793694 — intervention group
Group type: COMPARATOR
Intervention: Control group (donor blood only)
Number of subjects: 21
Study 6629620 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance fitness programme (1 1/4 hours per day)
Number of subjects: 716
Study 6629620 — intervention group
Group type: COMPARATOR
Intervention: Skill programme
Number of subjects: 716
Study 6629620 — intervention group
Group type: COMPARATOR
Intervention: Previous physical education programme (controls)
Number of subjects: 716
Study 6629620 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme (after phase one)
Number of subjects: 716
Study 6629620 — intervention group
Group type: COMPARATOR
Intervention: Formal teaching time loss (45-60 minutes)
Number of subjects: 716
Study 29532983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) target (<120 mm Hg)
Number of subjects: 5425
Study 29532983 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) target (<140 mm Hg)
Number of subjects: 5425
Study 27612499 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 281
Study 27612499 — intervention group
Group type: COMPARATOR
Intervention: No Diabetes Mellitus (non-DM)
Number of subjects: 281
Study 27612499 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Rutherford category
Number of subjects: 281
Study 27612499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) >1.4
Number of subjects: 281